Effect of oral contraceptives on the anticoagulant activity of protein S in plasma

Summary

We determined anticoagulant parameters that depend on protein S function in plasma, i.e.the APC-independent anticoagulant activity of protein S (expressed as pSR) and APC resistance determined with thrombin generation-based tests (expressed as APCsr) as well as plasma levels of total and free protein S and prothrombin in men, women not using oral contraceptives (OC), and in women using second or third generation OC. Thrombin generation in the APC resistance assays was initiated either with factor Xa (Xa-APCsr) or tissue factor (TF-APCsr). The APC-independent anticoagulant activity of protein S was highest in men (pSR=1.69) and gradually decreased from women not using OC (pSR=1.49) via women using second generation (pSR=1.35) to women using third generation OC (pSR=1.27). The pSR correlated inversely with nAPCsr determined with the tissue factor-based APC resistance test (TF-APCsr) but not with nAPCsr determined with the factor Xa-based assay (Xa-APCsr). Multiple linear regression analysis in which sex, OC use, and protein S and prothrombin levels were included as independent variables and the pSR, TF-APCsr or Xa-APCsr as dependent variables indicated that plasma protein S levels poorly predict the pSR and the TF-APCsr, but are the main determinant of the Xa-APCsr. This indicates that OC use alters the expression of protein S activity. This phenomenon can be caused by differences in modulation of the activity of protein S by other plasma proteins that change during OC use or by OC-induced changes in the protein S molecule that impair its anticoagulant activity. Functional impairment of protein S as a result of hormonal influence may, at least in part, contribute to the thrombotic risk of OC users.

Keywords

Protein S - oral contraceptives - APC-resistance - pSR - thrombosis

• References

• 1 Walker FJ. Regulation of activated protein C by a newprotein. A possible function for bovine protein S. J Biol Chem 1980; 255: 5521-4.
• 2 Walker FJ, Chavin I S, Fay PJ. Inactivation of factor VIII by activated protein C and protein S. Arch Biochem Biophys 1987; 252: 322-8.
• 3 Koedam JA, Meijers JC, Sixma JJ. et al. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-43.
• 4 Hackeng TM, van 't Veer C, Meijers JC. et al Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-8.
• 5 Heeb MJ, Mesters RM, Tans G. et al. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-7.
• 6 Heeb MJ, Rosing J, Bakker HM. et al. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A 1994; 91: 2728-32.
• 7 Koppelman SJ, Hackeng TM, Sixma JJ. et al. Inhibition of the intrinsic factor Xactivating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-71.
• 8 van Wijnen M, van't Veer C, Meijers JC. et al. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. Thromb Haemost 1998; 80: 930-5.
• 9 van't Veer C, Hackeng TM, Biesbroeck D. et al. Increased prothrombin activation in protein S-deficient plasma under flow conditions on endothelial cell matrix: an independent anticoagulant function of protein S in plasma. Blood 1995; 85: 1815-21.
• 10 Koenen RR, Tans G, van Oerle R. et al. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 2003; 102: 1686-92.
• 11 Mahasandana C, Suvatte V, Marlar RA. et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335: 61-2.
• 12 Mahasandana C, Suvatte V, Chuansumrit A. et al. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990; 117: 750-3.
• 13 Schwarz H, Fischer M, Hopmeier P. et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-300.
• 14 Comp PC, Nixon RR, Cooper MR. et al. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-8.
• 15 Faioni E, Valsecchi C, Palla A. et al. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997; 78: 1343-6.
• 16 Dykes AC, Walker ID, McMahon AD. et al. Astudy of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-41.
• 17 Boerger LM, Morris PC, Thurnau GR. et al. Oral contraceptives and gender affect protein S status. Blood 1987; 69: 692-4.
• 18 Liberti G, Bertina R, Rosendaal F. Hormonal state rather than age influences cut-off values of protein S: reevaluation of the thrombotic risk associatedwith protein Sdeficiency. Thromb Haemost 1999; 82: 1093-6.
• 19 Henkens CM, Bom VJ, Van der Schaaf W. et al. Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Thromb Haemost 1995; 74: 1271-5.
• 20 Tans G, Curvers J, Middeldorp S. et al. A randomized cross-over study on the effects of levonorgestreland desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
• 21 Dahlbäck B, Stenflo J.. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 1981; 78: 2512-6.
• 22 Persson KE, Hillarp A, Dahlbäck B. Analytical considerations for free protein S assays in protein S deficiency. Thromb Haemost 2001; 86: 1144-7.
• 23 Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261: 12022-7.
• 24 van de Poel RH, Meijers JC, Bouma BN.. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost 2001; 85: 761-5.
• 25 Legnani C, Cosmi B, Valdre L. et al. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 2003; 1: 112-7.
• 26 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 27 Koenen RR, Gomes L, Tans G. et al. The Ser460Pro mutation in recombinant protein S Heerlen does not affect its APC-cofactor and APC-independent anticoagulant activities. Thromb Haemost 2004; 91: 1105-14.
• 28 Sere KM, Janssen MP, Willems GM. et al. Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. Biochemistry 2001; 40: 8852-60.
• 29 Giri TK, Hillarp A, Hardig Y. et al. Anewdirect, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79: 767-72.
• 30 Bertina RM, van der Marel-van Nieuwkoop W, Loeliger EA. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemost 1979; 42: 1296-305.
• 31 Rosing J, Tans G, Nicolaes GA. et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
• 32 Curvers J, Thomassen MC, Nicolaes GA. et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
• 33 Curvers J, Christella M, Thomassen LG. et al. Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay. Thromb Haemost 2002; 87: 483-92.
• 34 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
• 35 Mackie IJ, Piegsa K, Furs SA. et al. Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over. Br J Haematol 2001; 113: 898-904.
• 36 Kemmeren JM, Algra A, Meijers JC. et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leidenmutation: a randomized trial. Blood 2004; 103: 927-33.
• 37 Borgel D, Gaussem P, Garbay C. et al. Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the gamma-carboxyglutamic acid-rich domain. Biochem J 2001; 360 (Pt 2) 499-506.
• 38 Tran S, Norstrom E, Dahlbäck B. Inhibition by prothrombin of individual activated protein C-mediated cleavages in factor Va. J Thromb Haemost 2003; 1 (Suppl. 01) Supplement July P1055.
• 39 Boinot C, Borgel D, Kitzis A. et al. Familial thrombophilia is an oligogenetic disease: involvement of the prothrombin G20210A, PROC and PROS gene mutations. Blood Coagul Fibrinolysis 2003; 14: 191-6.
• 40 Castaman G, Tosetto A, Cappellari A. et al. The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency. Blood Coagul Fibrinolysis 2000; 11: 321-6.